Market research
IGC India Globalization Capital Inc
AMEX USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 0.48
Profile
Instrument facts
- Exchange
- AMEX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 0.48
About
About India Globalization Capital Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Research context
India Globalization Capital Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the IGC discussion.
5 years, 7 months ago
India Globalization Capital, Inc is currently in a long term downtrend where the price is trading 5.5% below its 200 day moving average.
From a valuation standpoint, the stock is 62.6% more expensive than other stocks from the Industrials sector with a price to sales ratio of 86.2.
India Globalization Capital, Inc's total revenue sank by 81.2% to $108K since the same quarter in the previous year.
Its net income has dropped by 44.9% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 48.9% to $-2M since the same quarter in the previous year.
Based on the above factors, India Globalization Capital, Inc gets an overall score of 1/5.